MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, KALV made $49,078K in revenue. -$111,439K in net income. Net profit margin of -227.07%.

Income Overview

Revenue
$49,078K
Net Income
-$111,439K
Net Profit Margin
-227.07%
EPS
-$2.03
Unit: Thousand (K) dollars
Revenue Breakdown
    • Commercial expenses
    • Other sg&a
    • Clinical development
    • Others
Revenue Breakdown
    • Total operating expenses

Income Statement
2025-12-31
Product revenue, net
49,078
Cost of revenue
3,081
Research and development
33,371
Selling, general and administrative
124,663
Total operating expenses
161,115
Operating loss
-112,037
Interest income
5,789
Interest expense
12,895
Foreign currency exchange gain
30
Other income, net
8,556
Total other income
1,480
Loss before income tax (benefit) expense
-110,557
Income tax (benefit) expense
-1,033
Net loss
-109,524
Foreign currency translation loss
-1,004
Unrealized holding gain on marketable securities
316
Reclassification adjustment for realized holding gain on marketable securities included in net loss
1,227
Total other comprehensive (loss)
-1,915
Comprehensive loss
-111,439
Basic EPS
-2.03
Diluted EPS
-2.03
Basic Average Shares
53,870,007
Diluted Average Shares
53,870,007
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$111,439K Net loss-$109,524K Total othercomprehensive (loss)-$1,915K Income tax (benefit)expense-$1,033K Unrealized holding gain onmarketable securities$316K Other income, net$8,556K Interest income$5,789K Foreign currencyexchange gain$30K Loss before incometax (benefit)...-$110,557K Reclassification adjustment forrealized holding gain on...$1,227K Foreign currencytranslation loss-$1,004K Total other income$1,480K Commercial expenses$89,441K Interest expense$12,895K Other sg&a$35,780K Clinical development$14,723K Research expenses$12,851K Regulatory and qa expenses$5,239K Cost of product andservice sold$3,081K Operating loss-$112,037K Product revenue, net$49,078K Net loss-$109,524K Total other income-$1,480K Income tax expense(benefit), total-$1,033K Total operatingexpenses$161,115K Segment net loss-$109,524K Selling, general andadministrative$124,663K Research and development$33,371K Cost of revenue$3,081K

KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals, Inc. (KALV)